IPO registrations (S-1, F-1) · Registrants
COGNITION THERAPEUTICS INC
- SEC CIK
- 1455365 · filings on EDGAR ↗
- Former names
- COGNITION THERAPUTICS INC (2009–2010)
- Registration
- Form S-1, first filed 2021-07-19, last 2022-11-07; 2 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2021-10-12; declared effective 2021-10-07
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 2500 WESTCHESTER AVE, Purchase, NY 10577
- Ticker
- CGTX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- COGNITION THERAPEUTICS INC on the corporate pages
Offering terms
- Proposed price range
- $11.00–$13.00 per share (S-1/A filed 2021-10-04)
- Final price
- $12.00 per share, within the range (424B4 filed 2021-10-12, an initial public offering)
- Shares sold
- 3,768,116
- Gross proceeds
- $45,217,392 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CGTX
- Lead underwriters
- B. Riley Securities (2,499,275 shares)
- Syndicate
- Oppenheimer (1,318,841)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: COGNITION THERAPEUTICS, INC. Fuzzy (name and state)
- Federal award recipient: COGNITION THERAPEUTICS, INC. Fuzzy (name and state)
- Form D issuer: COGNITION THERAPEUTICS INC EXACT (CIK (EXACT))
- SEC filer: COGNITION THERAPEUTICS INC EXACT (CIK (EXACT))
- Person page: Ellen B Richstone Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 14
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-07-19 | S-1 | S-1 (registration) | COGNITION THERAPEUTICS INC | 0001104659-21-093246 ↗ |
| 2021-07-29 | S-1/A | S-1/A (amendment) | COGNITION THERAPEUTICS INC | 0001104659-21-097621 ↗ |
| 2021-08-20 | S-1/A | S-1/A (amendment) | COGNITION THERAPEUTICS INC | 0001104659-21-108070 ↗ |
| 2021-09-10 | S-1/A | S-1/A (amendment) | COGNITION THERAPEUTICS INC | 0001104659-21-114520 ↗ |
| 2021-10-04 | S-1/A | S-1/A (amendment) | COGNITION THERAPEUTICS INC | 0001104659-21-122299 ↗ |
| 2021-10-07 | S-1MEF | S-1MEF (added securities) | COGNITION THERAPEUTICS INC | 0001104659-21-124325 ↗ |
| 2021-10-07 | EFFECT | EFFECT (declared effective) | COGNITION THERAPEUTICS INC | 9999999995-21-003810 ↗ |
| 2021-10-12 | 424B4 | 424B4 (final prospectus) | COGNITION THERAPEUTICS INC | 0001104659-21-125316 ↗ |
| 2022-11-07 | S-1 | S-1 (registration) | COGNITION THERAPEUTICS INC | 0001104659-22-115489 ↗ |
| 2022-11-09 | EFFECT | EFFECT (declared effective) | COGNITION THERAPEUTICS INC | 9999999995-22-003250 ↗ |
| 2022-11-14 | 424B4 | 424B4 (final prospectus) | COGNITION THERAPEUTICS INC | 0001104659-22-117372 ↗ |
| 2023-01-03 | EFFECT | EFFECT (declared effective) | COGNITION THERAPEUTICS INC | 9999999995-23-000027 ↗ |
| 2024-01-08 | 424B4 | 424B4 (final prospectus) | COGNITION THERAPEUTICS INC | 0001104659-24-002241 ↗ |
| 2024-01-08 | EFFECT | EFFECT (declared effective) | COGNITION THERAPEUTICS INC | 9999999995-24-000062 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-10-04 | S-1/A | registration statement | $11.00–$13.00 | 3,350,000 | - | Nasdaq CGTX | 2 | primary document; range, shares headline, cover names 2 | document ↗ | |
| 2021-10-12 | 424B4 | final prospectus | $12.00 | 3,768,116 | $45,217,392 | Nasdaq CGTX | 2 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BIOS Memory SPV I, LP | Director,TenPercentOwner; TenPercentOwner | 12 | 2021–2026 | ||
| Breedlove Mark H. | Director | 2 | 2021 | ||
| Fletcher Aaron G.L. | Director; Director,TenPercentOwner | 16 | 2021–2026 | ||
| Golden Seeds Cognition Therapeutics LLC | TenPercentOwner | 3 | 2021–2022 | ||
| Khattar Jack A. | Director | 7 | 2021–2026 | ||
| Monia Brett P | Director | 7 | 2021–2026 | ||
| O'Brien James Michael | Officer | Chief Financial Officer | 4 | 2021–2022 | |
| Ogden CAP Associates, LLC | TenPercentOwner | 2 | 2021 | ||
| Ricciardi Lisa | Director,Officer | CEO & President | 17 | 2021–2026 | |
| Wallace Peggy | Director | 10 | 2021–2026 | ||
| RICHSTONE ELLEN B | Director | 9 | 2021–2026 | person page Fuzzy | |
| Caggiano Anthony | Officer | Chief Medical Officer | 13 | 2021–2026 | |
| BIOS Advisors GP, LLC | Director,TenPercentOwner; TenPercentOwner | 13 | 2022–2026 | ||
| BIOS Capital Management, LP | Director,TenPercentOwner; TenPercentOwner | 13 | 2022–2026 | ||
| BIOS Equity Partners III, LP | Director,TenPercentOwner; TenPercentOwner | 9 | 2022–2025 | ||
| Bios Equity Partners II, LP | Director,TenPercentOwner; TenPercentOwner | 10 | 2022–2026 | ||
| Bios Equity Partners, LP | Director,TenPercentOwner; TenPercentOwner | 13 | 2022–2026 | ||
| BIOS Fund III, LP | Director,TenPercentOwner; TenPercentOwner | 9 | 2022–2025 | ||
| BIOS Fund III NT, LP | Director,TenPercentOwner; TenPercentOwner | 9 | 2022–2025 | ||
| BIOS Fund III QP, LP | Director,TenPercentOwner; TenPercentOwner | 9 | 2022–2025 | ||
| BIOS Fund II, LP | Director,TenPercentOwner; TenPercentOwner | 10 | 2022–2026 | ||
| BIOS Fund II NT, LP | Director,TenPercentOwner; TenPercentOwner | 9 | 2022–2025 | ||
| BIOS Fund II QP, LP | Director,TenPercentOwner; TenPercentOwner | 10 | 2022–2026 | ||
| BIOS Fund I, LP | Director,TenPercentOwner; TenPercentOwner | 10 | 2022–2026 | ||
| BIOS Fund I QP, LP | Director,TenPercentOwner; TenPercentOwner | 10 | 2022–2026 | ||
| BIOS Memory SPV II, LP | Director,TenPercentOwner; TenPercentOwner | 9 | 2022–2025 | ||
| BP Directors, LP | Director,TenPercentOwner; Other | 4 | 2022–2025 | ||
| Cavu Advisors, LLC | Director,TenPercentOwner; TenPercentOwner | 12 | 2022–2025 | ||
| Cavu Management, LP | Director,TenPercentOwner; TenPercentOwner | 12 | 2022–2025 | ||
| Kreis Leslie W. | Director; Director,TenPercentOwner; TenPercentOwner | 11 | 2022–2025 | ||
| Einhorn Andrew J. | Officer | Interim CFO | 1 | 2022 | |
| Doyle John Brendan | Officer | Chief Financial Officer | 13 | 2023–2026 | |
| Bios Clinical Opportunity Fund, LP | Director,TenPercentOwner | 1 | 2023 | ||
| Bios Equity COF, LP | Director,TenPercentOwner | 1 | 2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2018-11-28 | COGNITION THERAPEUTICS INC | Biotechnology | $8,000,000 | $1,646,868 | 28 | 1 |
| 2018-03-15 | COGNITION THERAPEUTICS INC | Biotechnology | $5,000,000 | $2,409,575 | 31 | 1 |
| 2016-11-30 | COGNITION THERAPEUTICS INC | Biotechnology | $6,500,000 | $4,176,324 | 50 | 2 |
| 2016-03-31 | COGNITION THERAPEUTICS INC | Biotechnology | $4,500,000 | $3,470,072 | 41 | 1 |
| 2014-04-01 | COGNITION THERAPEUTICS INC | Biotechnology | $16,568,545 | $15,834,018 | 56 | 3 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | COGNITION THERAPEUTICS, INC. | NY | State business registries | name and state |
| Federal award recipient | COGNITION THERAPEUTICS, INC. | NY | Federal spending (USAspending) | name and state |
| Form D issuer | COGNITION THERAPEUTICS INC | PA | Form D private offerings | CIK (EXACT) |
| SEC filer | COGNITION THERAPEUTICS INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | Ellen B Richstone | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), NY first:
- Acorda Therapeutics, Inc. NY
- BRAINSTORM CELL THERAPEUTICS INC. NY
- ANAVEX LIFE SCIENCES CORP. NY
- CytRx Oncology Corp NY
- Omrix Biopharmaceuticals, Inc. NY
- Protara Therapeutics, Inc. NY
- Bavarian Nordic A/S / ADR NY
- Qrons Inc. NY
- Prevail Therapeutics Inc. NY
- MeiraGTx Holdings plc NY
In other datasets, the same topic (Health) in NY:
- Nonprofit: AABR FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health